New blood filter aims to save lives in liver failure and sepsis

NCT ID NCT06562803

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a special blood-filtering device (DPCAS+LPE) in 192 adults with acute-on-chronic liver failure and sepsis. The device removes harmful inflammatory substances from the blood. Researchers will compare survival rates and organ function between patients receiving this device plus standard care versus standard care alone. The goal is to see if this approach can reduce deaths within 4 and 12 weeks.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
double plasma cytokine adsorption system with sequential low-dose plasma exchange (DPCAS+LPE) device
What this could lead to
If successful, this could offer a new treatment option to improve survival in patients with severe liver failure complicated by sepsis.
What could go wrong
This is a mid-stage trial with 192 participants, so results may not apply to all patients. The device is complex and carries risks like bleeding or infection.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE-ON-CHRONIC LIVER FAILURE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Acute-On-Chronic Liver Failure infectious disease with sepsis Sepsis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Third Affiliated Hospital of Sun Yat-sen University

    RECRUITING

    Guangzhou, Guangdong, 510630, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.